David Wong,
Felix and Mildred Yip Endowed Chair in Dentistry; Director for UCLA Center for Oral/Head & Neck Oncology Research,
University of California-Los Angeles
David T.W. Wong DMD, DMSc is Felix & Mildred Yip Endowed Professor, Associate Dean of Research and Director of the Oral/Head and Neck Oncology Research Center at UCLA. Dr. Wong is an active scientist in oral cancer and saliva diagnostics research. He has authored over 280 peer reviewed scientific publications. He is a fellow of the American Association for the Advancement of Sciences (AAAS), past member of the ADA Council of Scientific Affairs and the past president of American Association of Dental Research (AADR).
Saliva-Based Detection of Actionable EGFR Mutation in Lung Cancer Patients
Monday, 16 November 2015 at 10:00
Add to Calendar ▼2015-11-16 10:00:002015-11-16 11:00:00Europe/LondonSaliva-Based Detection of Actionable EGFR Mutation in Lung Cancer PatientsSELECTBIOenquiries@selectbiosciences.com
Constitutive activation of epithelial growth factor receptor (EGFR) is prevalent in epithelial cancers, particularly in non-small-cell lung carcinoma (NSCLC). EGFR mutation predicts sensitivity to EGFR-targeted therapy and mutation detection is mainly based on tissue biopsy, which is invasive, expensive and time-consuming. Non-invasive, real-time, point-of-care, inexpensive detection and monitoring of EGFR mutations in NSCLC patients is highly desirable. We developed a novel core technology, Electric Field-Induced Release and Measurement (EFIRM), relying on a multiplexible electrochemical sensor that can detect EGFR mutations directly from body fluids. EFIRM for EGFR mutation detection was established in vitro, and correlated with tumor size from xenografted mice. In clinical application, we demonstrated that EFIRM can detect EGFR mutations from saliva and serum of 22 NSCLC patients. And finally, a blinded test was performed on saliva from 40 NSCLC patient saliva samples. The receiver operating characteristic analysis indicated that EFIRM detected the exon 19 deletion with an area under the curve (AUC) of 0.94 and the L858R mutation with an AUC of 0.96. Our data indicate that EFIRM is effective, accurate, rapid, user-friendly, and cost effective for the detection of EGFR mutations in saliva of NSCLC patients.
Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-11-16 10:00:002015-11-16 11:00:00Europe/LondonSaliva-Based Detection of Actionable EGFR Mutation in Lung Cancer PatientsSELECTBIOenquiries@selectbiosciences.com
